Understanding the
Unmet Need
Major Safety and
Tolerability Challenges Unnecessary Exposure to
Extended Endocrine Therapy Side Effects Lead
to Noncompliance
About Breast Cancer Index (BCI)
About BCI How is BCI Used? Predictive Studies Prognostic Studies Health Economics Study
Patient Scenarios Ordering Information Videos News & Press
bioTheranostics Privacy Statement Terms and Conditions Site Map

bioTheranostics, Inc.
9640 Towne Centre Drive | Suite 200
San Diego, CA 92121
bioTheranostics.com

US and International: +1 (858) 587-5870
Fax: +1 (858) 587-5874
Client Services: +1 (877) 886-6739
Billing Information: +1 (858) 682-9279

© 2015 bioTheranostics, Inc.
Breast Cancer Index and BCI are service marks of bioTheranostics, Inc.

< Back

Tour the Test Report

Prognostic Score

  • 0 - 10
  • Individualized risk of late recurrence*

*If ordered at time of diagnosis, test report also provides overall (years 0-10), early (0-5 year), and late (5-10 year) risk of recurrence

Prognostic Study PROGNOSTIC STUDIES

Predictive Score

  • Predictive of likelihood of benefit from extended endocrine therapy
  • HIGH or LOW (binary result)
Predictive Study PREDICTIVE STUDIES

Side Effects Lead to Noncompliance

Discontinuation ranges from 31% – 73% during the first 5 years.1,2

Year-over-year discontinuation rate of tamoxifen in women with early-stage breast cancer

Discontinuation Rate Graph

This effect continues with extended endocrine therapy.

Reasons for Discontinuation2

Although extended endocrine therapy is often positioned as less difficult to take than chemotherapy, current guidelines recognize side effects and their role in non-compliance

Expand
Reasons for Discontinuation Chart

In the extended treatment setting (Years 5-10), endocrine therapies have well-established tolerability issues that contribute to discontinuation4

Non-adherence impacts patient outcomes4

[BCI Predictive] biomarker should allow many women to avoid unnecessary treatment and for the focus to center on those in most need of therapy. This, in turn, could improve compliance with medication and further improve outcomes.

— Sgroi, et al. BCI-MA.17 study, J Natl Cancer Inst., 20137

Learn about the BCI test
Download the BCI Order Form

References

  1. Sgroi DC, et al. J Natl Cancer Inst. 2013;105:1036-1042.
  2. Sgroi DC, et al. Lancet Oncol. Published online September 12, 2013. http://dx.doi.org/10.1016/ S1470-2045(13)70387-5.
  3. Zhang Y, et al. Clin Cancer Res. 2013;19:4196-4205.
  4. Goss PE, et al. N Engl J Med. 2003;349:1793-1802.
  5. Burstein HJ, et al. J Clin Oncol. 2014;32:1-16

Breast Cancer Index Indications for Use and Limitations

BCI provides a quantitative assessment of the likelihood of distant recurrence in patients diagnosed with ER+ node-negative breast cancer, and prediction of likelihood of benefit from extended (>5 year) endocrine therapy in patients who are recurrence-free after an initial 5 years of adjuvant endocrine therapy. Treatment decisions require correlation with all other clinical findings. This test was developed and its performance characteristics determined by bioTheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. bioTheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high-complexity clinical laboratory testing.